Analysis the relationship of HBV BCP A1762T/G1764A double mutation with HBV related acute on chronic liver failure. [Article in Chinese]
Yan T, Li K, Su HB, Liu XY, Zang H, Wang HF.
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2010 Jun;24(3):190-2.
Liver Failure Treatment and Research Center, 302 Hospital, Beijing 100039, China.
To analysis the relationship between HBV BCP A1762T/G1764A double mutation with acute on chronic liver failure (ACLF).
HBV BCP A1762T/G1764A double mutation was detected in 166 HBV chronic infection patients by nested PCR and direct DNA sequencing. The mutation rate was compared among the patients with different disease course.
Among 166 patients, 45 patients, 45 patients, 49 patients and 27 patients were diagnosed as chronic hepatitis B (CHB), liver cirrhosis (LC), ACLF and hepatocellular carcinoma (HCC), respectively. A1762T/G1764A double mutation rate was 40.0% (18/45), 84.4% (38/45), 73.5% (36/49) and 92.6% (25/27) respectively in different groups. However, A1762T/G1764A double mutation rate has no difference between ACLF based on CHB and LC (P = 0.502) and between patients with HBeAg positive and negative (P = 0.735). HBV DNA level (log) of patients with A1762T/G1764A double mutation was 5.68 +/- 1.36, lower than but having no significant statistic difference compared to patients without the double mutation (6.14 +/- 1.81, P = 0.075).
A1762T/G1764A double mutation has a close relationship with the progress of HBV-infection diseases, but is not specific to patients with ACLF. And patients with BCP double mutation have similar HBV DNA levels and HBeAg status with patients without the double mutation.